NCT01469832View on ClinicalTrials.gov

Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 13, 2011

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Stargardt's Macular Dystrophy
Interventions
BIOLOGICAL

MA09-hRPE

"* Cohort 1 50,000 cells~* Cohort 2 100,000 cells~* Cohort 2a Better Vision 100,000 cells~* Cohort 3 150,000 cells~* Cohort 4 200,000 cells"

Trial Locations (3)

EH1 3EG

Lothian Health Board Headquarters at Waverley Gate, Edinburgh

EC1V2PD

Moorefields Eye Hospital NHS Foundation Trust, London

NE7 7DN

Newcastle on Tyne NHS Foundation Trust, Newcastle upon Tyne

All Listed Sponsors
lead

Astellas Institute for Regenerative Medicine

INDUSTRY

NCT01469832 - Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) | Biotech Hunter | Biotech Hunter